MedPath

A Multi-omics Study of Adenomyosis

Conditions
Genomics
Endometriosis
Ectopic Endometrium
Metabolomics
Adenomyosis
Eutopic Endometrium
Transcriptomics
Registration Number
NCT03742843
Lead Sponsor
Lei Li
Brief Summary

This study aims to analyze the multi-omics results between eutopic endometrium, adenomyosis and endometriosis of patients diagnosed of adenomyosis with and without endometriosis. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the pathogenesis of adenomyosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Confirmed adenomyosis and/or endometriosis
  • Signed an approved informed consents
  • Feasible for biopsy
Exclusion Criteria
  • Not meeting all of the inclusion criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Frequencies of somatic driving mutationsTwo years

The differences of distributions and frequencies of somatic driving mutations will be compared between eutopic endometrium and ectopic endometrium by whole exome sequencing.

Secondary Outcome Measures
NameTimeMethod
Frequencies of alteration of RNA expressionTwo years

The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between eutopic endometrium and ectopic endometrium by transcriptome sequencing.

Progression-free survivalFive years

Progression-free survival between patients with differential expressed multi-omics will be compared.

Frequencies of alteration of protein expression and signal pathwayTwo years

The alteration of protein expression and signal pathway will be compared between eutopic endometrium and ectopic endometrium by metabolomic sequencing

Trial Locations

Locations (1)

Lei Li

🇨🇳

Beijing, Beijing, China

Lei Li
🇨🇳Beijing, Beijing, China
Lei Li, MD
Contact
13911988831
lileigh@163.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.